Sputum antibiotic concentrations: Implications for treatment of cystic fibrosis lung infection

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Pediatric Pulmonology

• Publication date

  2007-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ppul.20671PMID 17902147
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis.

  2007cited by this paper
• Combination Antibiotic Susceptibility Testing to Treat Exacerbations of Cystic Fibrosis Associated With Multiresistant Bacteria: A Randomised, Double-blind, Controlled Clinical Trial

  2007cited by this paper
• Effectiveness of Cephalosporins in the Sputum of Patients with Nosocomial Bronchopneumonia

  2006cited by this paper
• Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES).

  2005cited by this paper
• Intravenous versus Nebulized Ceftazidime in Ventilated Piglets with and without Experimental Bronchopneumonia: Comparative Effects of Helium and Nitrogen

  2005cited by this paper
• Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis.

  2005cited by this paper
• Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial.

  2005cited by this paper
• Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use

  2005cited by this paper
• Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.

  2005cited by this paper
• Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.

  2003cited by this paper
• Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.

  2003cited by this paper
• Delivering Antibacterials to the Lungs

  2002cited by this paper
• Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.

  2002cited by this paper
• Determination of minimum inhibitory concentrations.

  2001cited by this paper
• In vitro susceptibility testing of BMS-284756 by the BSAC standardized disc testing method.

  2001cited by this paper
• Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients.

  2001cited by this paper
• Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients.

  2001cited by this paper
• Determination of gentamicins C(1), C(1a), and C(2) in plasma and urine by HPLC.

  2000cited by this paper
• Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms

  2000cited by this paper
• Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

  2000cited by this paper
• Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis

  1999cited by this paper
• Activities of Tobramycin and Six Other Antibiotics against Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis

  1999cited by this paper
• Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa.

  1999cited by this paper
• Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo

  1999cited by this paper
• Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria

  1999cited by this paper
• Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis.

  1999cited by this paper
• Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis

  1998cited by this paper
• Dosing of Aminoglycosides To Rapidly Attain Pharmacodynamic Goals and Hasten Therapeutic Response by Using Individualized Pharmacokinetic Monitoring of Patients with Pneumonia Caused by Gram-Negative Organisms

  1998cited by this paper
• Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model

  1997cited by this paper
• Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics.

  1997cited by this paper
• Pharmacokinetics of Ceftazidime in Adult Cystic Fibrosis Patients During Continuous Infusion and Ambulatory Treatment at Home

  1994cited by this paper
• Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing

  1993cited by this paper
• Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin

  1992cited by this paper
• Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance

  1992cited by this paper
• Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia

  1991cited by this paper
• Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers

  1990cited by this paper
• The pharmacokinetics and sputum penetration of ampicillin and amoxycillin following simultaneous i.v. administration.

  1990cited by this paper
• Concentrations of cefixime in bronchial mucosa and sputum.

  1990cited by this paper
• Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

  1988cited by this paper
• Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

  1987cited by this paper
• Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa.

  1987cited by this paper
• Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.

  1985cited by this paper
• Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis.

  1984cited by this paper
• Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion

  1981cited by this paper
• Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis

  1980cited by this paper
• The concentration of tobramycin in bronchial secretions.

  1979cited by this paper
• A method for testing for synergy with any number of agents.

  1978cited by this paper
• The protein binding of ticarcillin and tobramycin.

  1976cited by this paper
• Serum Protein Binding of the Aminoglycoside Antibiotics

  1972cited by this paper

• An Observational Cohort Study of Targeted Antibiotic Treatments of Cystic Fibrosis Exacerbations

  2026influential citation
• Hijacking anaerobic metabolism to restore antibiotic efficacy in Pseudomonas aeruginosa

  2025cites this paper
• The role of hypermutation and collateral sensitivity in antimicrobial resistance diversity of Pseudomonas aeruginosa populations in cystic fibrosis lung infection

  2024cites this paper
• Antibiotic resistant bacteria survive treatment by doubling while shrinking

  2024cites this paper
• The Role of Hypermutation and Collateral Sensitivity in Antimicrobial Resistance Diversity of Pseudomonas aeruginosa Populations in Cystic Fibrosis Lung Infection

  2023cites this paper
• Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish

  2023cites this paper
• Lytic Bacteriophage Is a Promising Adjunct to Common Antibiotics across Cystic Fibrosis Clinical Strains and Culture Models of Pseudomonas aeruginosa Infection

  2023cites this paper
• The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia

  2022cites this paper
• Ceftazidime dosing in obese patients: is it time for more?

  2022cites this paper
• Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways

  2021cites this paper
• Building reusable phage and antibiotic treatments via exploitation of bacteria-phage coevolutionary dynamics

  2021cites this paper
• Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions

  2021cites this paper
• Antibiotics Drive Expansion of Rare Pathogens in a Chronic Infection Microbiome Model

  2021cites this paper
• LC-MS detection of antibiotic agents in sputum from persons with cystic fibrosis.

  2020cites this paper
• Cystic Fibrosis: A Multi-Organ System Approach

  2020influential citation
• Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation.

  2020cites this paper
• Nontuberculous Mycobacterium

  2020cites this paper
• Comparative Evolutionary Patterns of Burkholderia cenocepacia and B. multivorans During Chronic Co-infection of a Cystic Fibrosis Patient Lung

  2020influential citation
• Biodegradable microparticles designed to efficiently reach and act on cystic fibrosis mucus barrier.

  2019cites this paper
• Mutagenesis Induced by Sub-Lethal Doses of Ciprofloxacin: Genotypic and Phenotypic Differences Between the Pseudomonas aeruginosa Strain PA14 and Clinical Isolates

  2019cites this paper
• Nontuberculous Mycobacterial Infections in Cystic Fibrosis.

  2019cites this paper
• In vitro Interactions of Pseudomonas aeruginosa With Scedosporium Species Frequently Associated With Cystic Fibrosis

  2019cites this paper
• Diversification of Pseudomonas aeruginosa within the cystic fibrosis lung and its effects on antibiotic resistance.

  2018cites this paper
• Development and validation of an LC tandem MS assay for the quantification of &bgr;-lactam antibiotics in the sputum of cystic fibrosis patients

  2018cites this paper
• DEVELOPMENT AND VALIDATION OF A SEMI-PHYSIOLOGICAL PHARMACOKINETIC (PBPK) MODEL TO PREDICT SYSTEMIC AND PULMONARY EXPOSURES AFTER INTRAVENOUS, ORAL ADMINISTRATION AND PULMONARY INHALATION OF SELECTED DRUGS, BUDESONIDE, TOBRAMYCIN AND CIPROFLOXACIN, IN HUMANS

  2018cites this paper
• Variation in treatment strategies for the eradication of Pseudomonas aeruginosa in primary ciliary dyskinesia across European centers

  2018cites this paper
• Cystic fibrosis: treatment and prevention of pulmonary exacerbations

  2017cites this paper
• Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis

  2017cites this paper
• Within-host Diversification of Pseudomonas aeruginosa in the Cystic Fibrosis Airways and its Effects on Antimicrobial Resistance

  2017cites this paper
• Strong Shear Flow Persister Bacteria Resist Mechanical Washings on the Surfaces of Various Polymer Materials

  2017cites this paper
• Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Determine Optimal Dosing 1 of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Cystic 2 Fibrosis

  2017cites this paper
• Reactive oxygen species drive evolution of pro-biofilm variants in pathogens by modulating cyclic-di-GMP levels

  2016cites this paper
• Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota.

  2016cites this paper
• Nontuberculous Mycobacterial Infections in Cystic Fibrosis.

  2015cites this paper
• Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.

  2015cites this paper
• Nontuberculous mycobacterial infections in cystic fibrosis.

  2015cites this paper
• Nontuberculous Infections in Cystic Fibrosis

  2015cites this paper
• Clinical and in vitro evidence for the antimicrobial therapy in Burkholderia cepacia complex infections

  2015cites this paper
• Infections in chronic lung diseases 2 Antimicrobial resistance in the respiratory microbiota of people with cystic fi brosis

  2014cites this paper
• Aminoglycosides : de la théorie à la pratique

  2014cites this paper
• Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.

  2014cites this paper
• Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis.

  2014cites this paper
• aeruginosaEvolution of Pseudomonas Ciprofloxacin Resistance during Long-Term Rapid Development of High-Level Sublethal Ciprofloxacin Treatment Leads to

  2014cites this paper
• Sub‐lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogen Pseudomonas aeruginosa

  2013cites this paper
• Resistance Development of Cystic Fibrosis Respiratory Pathogens When Exposed to Fosfomycin and Tobramycin Alone and in Combination under Aerobic and Anaerobic Conditions

  2013cites this paper
• Sublethal Ciprofloxacin Treatment Leads to Rapid Development of High-Level Ciprofloxacin Resistance during Long-Term Experimental Evolution of Pseudomonas aeruginosa

  2013cites this paper
• Novel therapeutic strategies to counter Pseudomonas aeruginosa infections

  2012cites this paper
• Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections.

  2012cites this paper
• Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.

  2012cites this paper
• Photodynamic Antimicrobial Chemotherapy (PACT) in combination with antibiotics for treatment of Burkholderia cepacia complex infection.

  2012cites this paper
• Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant Stenotrophomonas maltophilia from Cystic Fibrosis Patients

  2012cites this paper
• Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas

  2010cites this paper
• Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations.

  2010cites this paper
• Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity

  2010cites this paper
• Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.

  2010cites this paper
• In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria.

  2009cites this paper
• Implementation of European standards of care for cystic fibrosis--control and treatment of infection.

  2009cites this paper
• Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.

  2009cites this paper
• In Vitro Activities of a Novel Nanoemulsion against Burkholderia and Other Multidrug-Resistant Cystic Fibrosis-Associated Bacterial Species

  2008cites this paper